NewsRelease

ResearchPoster Presented at the New Jersey Cancer Retreat for New CancerSerum Biomarker Panel

MONMOUTHJUNCTION, NJ, June 7, 2017 -- Biotech Support Group presented aposter describing a biomarker panel of cancer dysregulation derivedfrom serum proteomic profiles, at the New Jersey Cancer Retreat heldon May 25, 2017 in New Brunswick, NJ.

Theposter authors and title are:

HaiyanZheng¹;Swapan Roy²;Amenah Soherwardy¹;Seema Rahman²;Matthew Kuruc²,¹RutgersCenter for Integrative Proteomics, Piscataway, NJ; ²BiotechSupport Group LLC, Monmouth Junction, NJ, entitled “StromaLiquid Biopsy - Proteomic Profiles for Cancer Biomarkers”

Inbrief, while the landscape of cancer-associated DNA mutations hassupported the initial concepts for liquid biopsy, it is nowoverwhelmingly apparent that throughout cancer progression, there arenecessary adaptive microenvironments to support metastatic disease.We now present evidence that some of the essential interactionsbetween stroma and proliferating cells can in part, be monitoredthrough the protein response that tracksinto the vascularized tumor and re-proportions the extracellularproteins (serum) found in the general blood circulation. These patentpending proteomic patterns can now be reported as a Stroma LiquidBiopsy™.

“Herewe demonstrate that our serum proteome separations workflow producesvery unique data that cannot be obtained by other methods. Our nextgoal is to associate this knowledge and data to establishrelationships with client supplied samples characterized forprogressive disease or response to therapies, ultimately achievingbiomarkers useful in the clinic. Consequently this cancer biomarkerprofile can now be commercialized for many different applicationsincluding early detection, oncology drug development and personalizedtherapy decisions.”states Swapan Roy, Ph.D., President and Founder of Biotech SupportGroup. 

Todownload the poster, visit:

http://www.biotechsupportgroup.com/v/vspfiles/templates/257/pdf/NJ%20Cancer%20Retreat%20Stroma%20Liquid%20Biopsy%20Poster.pdf

AboutBiotech Support Group LLC

Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ forlipid adsorption, HemogloBind™ and HemoVoid™ forhemoglobin removal, and NuGel™ for functional proteomics. Fromthese innovations, the company has acquired knowledgebase andbiomarker intellectual property assets that support discoveries ofprotein markers from blood, with special emphasis on early detectionand personalized medical decisions for cancer patients. For moreinformation, go tohttp://www.biotechsupportgroup.com

Contact:
MatthewKuruc 732-274-2866

[email protected]